Rituximab Not Noninferior to Ocrelizumab for Relapsing-Remitting MS 0 14.06.2023 18:59 «TDN» (tdn.com) WEDNESDAY, June 14, 2023 (HealthDay News) -- For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology. Партнёры Smi24.net Все новости за 24 часа Музыкальные новости Агрегатор новостей 24СМИ
